Cardiovascular risk in the young type 1 diabetes population with a low 10-year, but high lifetime risk of cardiovascular disease

Diabetes, Obesity and Metabolism

Volumn 15, Issue 3, 2013, Pages 198-203

  McVeigh, G E ^b   Gibson, W ^a   Hamilton, P K ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Diabetic complications; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C;

ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MICROALBUMINURIA; MICROANGIOPATHY; MORBIDITY; MUSCLE ISCHEMIA; PRACTICE GUIDELINE; PROBABILITY; PUBERTY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK MANAGEMENT;

EID: 84873099974     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12013     Document Type: Review

References (55)

1. Laing SP, Swerdlow AJ, Slater SD et al. Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 2003; 46: 760-765.
2. Dahl-Jørgensen K, Larsen JR, Hanssen KF. Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment? Diabetologia 2005; 48: 1445-1453.
3. Margeirsdottir HD, Larsen JR, Brunborg C et al. Norwegian Study Group for Childhood Diabetes. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. Diabetologia 2008; 51: 554-561.
4. Skrivarhaug T, Bangstad HJ, Stene LC et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006; 49: 298-305.
5. van Vliet M, Van der Heyden JC, Diamant M et al. Overweight is highly prevalent in children with type 1 diabetes and associates with cardiometabolic risk. J Pediatr 2010; 156: 923-929.
6. Berenson GS. Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa Heart Study. Am J Cardiol 2002; 90: 3L-7L.
7. Berenson GS, Srinivasan SR, Bao W et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338: 1650-1656.
8. Silverstein J, Haller M. Coronary artery disease in youth: present markers, future hope? J Pediatr 2010; 157: 523-524.
9. Marcovecchio ML, Tossavainen PH, Dunger DB. Prevention and treatment of microvascular disease in childhood type 1 diabetes. Br Med Bull 2010; 94: 145-164.
10. Silverstein J, Klingensmith G, Copeland K et al. American Diabetes Association. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28: 186-212.
11. Donaghue KC, Chiarelli F, Trotta D et al. Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatr Diabetes 2009; 10(Suppl 12): 195-203.
12. Guidelines ADA. Recommendations for type 2 diabetes therapy. Diabetes Care 2012; 35(Suppl 1): S11-63.
13. Wadén J, Forsblom C, Thorn LM et al. Finnish Diabetic Nephropathy Study Group. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 2009; 58: 2649-2655.
14. McCrindle BW, Urbina EM, Dennison BA et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115: 1948-1967.
15. Lockhart CJ, Hamilton PK, Quinn CE et al. End-organ dysfunction and cardiovascular outcomes: the role of the microcirculation. Clin Sci 2009; 116: 175-190.
16. Minson CT, Green DJ. Measures of vascular reactivity: prognostic crystal ball or Pandora's box? J Appl Physiol 2008; 105: 398-399.
17. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-1685.
18. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350: 48-58.
19. Moore DJ, Gregory JM, Kumah-Crystal YA et al. Mitigating micro-and macro-vascular complications of diabetes beginning in adolescence. Vasc Health Risk Manag 2009; 5: 1015-1031.
20. Daneman D. Early diabetes-related complications in adolescents: risk factors and screening. Horm Res 2005; 63: 75-85.
21. Rossing P, Hougaard P, Borch-Johnsen K et al. Predictors of mortality in insulin dependent diabetes: 10year observational follow up study. BMJ 1996; 313: 779-784.
22. Cohn JN. Arterial stiffness, vascular disease, and risk of cardiovascular events. Circulation 2006; 113: 601-603.
23. Serné EH, de Jongh RT, Eringa EC et al. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 2007; 50: 204-211.
24. Cheung N, Wang JJ, Rogers SL et al. ARIC (Atherosclerosis Risk In Communities) Study Investigators. Diabetic retinopathy and risk of heart failure. J Am Coll Cardiol 2008; 51: 1573-1578.
25. Spinetti G, Kraenkel N, Emanueli C et al. Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies. Cardiovasc Res 2008; 78: 265-273.
26. Touyz RM. Vascular remodeling, retinal arteries, and hypertension. Hypertension 2007; 50: 603-604.
27. Kramer CK, Rodrigues TC, Canani LH et al. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care 2011; 34: 1238-1244.
28. Orchard TJ, Secrest AM, Miller RG et al. In the absence of renal disease, 20year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010; 53: 2312-2319.
29. Lehto S, Rönnemaa T, Pyörälä K et al. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol 1999; 19: 1014-1019.
30. Orchard TJ, Olson JC, Erbey JR et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003; 26: 1374-1379.
31. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
32. Nathan DM, Cleary PA, Backlund JY et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 22: 2643-2653.
33. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
34. Greenland P, Alpert JS, Beller GA et al. American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56: e50-103.
35. Echouffo-Tcheugui JB, Ogunniyi MO, Kengne AP. Estimation of absolute cardiovascular risk in individuals with diabetes mellitus: rationale and approaches. ISRN Cardiol 2011; 2011: 242656.
36. Christians T. Cardiovascular risk tables. BMJ 2008; 336: 1445-1446.
37. Donaghue KC, Chiarelli F, Trotta D et al. International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2006-2007. Microvascular and macrovascular complications. Pediatr Diabetes 2007; 8: 163-170.
38. Management of diabetes, a national guideline. SIGN 2010; 166: 1-170. Available from URL: http://www.sign.ac.uk/pdf/sign116.pdf.
39. Girach A, Vignati L. Diabetic microvascular complications-can the presence of one predict the development of another? J Diabetes Complications 2006; 20: 228-237.
40. Howard BV, Best LG, Galloway JM et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 2006; 29: 391-397.
41. Shah PK. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? J Am Coll Cardiol 2010; 56: 98-105.
42. Cohn JN, Duprez DA. Time to foster a rational approach to preventing cardiovascular morbid events. J Am Coll Cardiol 2008; 52: 327-329.
43. Diamond GA, Kaul S. The things to come of SHAPE: Cost and effectiveness of cardiovascular prevention. Am J Cardiol 2007; 99: 1013-1015.
44. Article: Health Economics. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012; 29: 855-862.
45. Hlatky MA, Greenland P, Arnett DK et al. American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119: 2408-2416.
46. Nambi V, Chambless L, Folsom AR et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010; 55: 1600-1607.
47. Becker A, Leber AW, Becker C et al. Predictive value of coronary calcifications for future cardiac events in asymptomatic patients with diabetes mellitus: a prospective study in 716 patients over 8 years. BMC Cardiovasc Disord 2008; 8: 27.
48. Elkeles RS, Godsland IF, Feher MD et al. PREDICT Study Group. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J 2008; 29: 2244-2251.
49. Scholte AJ, Schuijf JD, Kharagjitsingh AV et al. Prevalence of coronary artery disease and plaque morphology assessed by multi-slice computed tomography coronary angiography and calcium scoring in asymptomatic patients with type 2 diabetes. Heart 2008; 94: 290-295.
50. Becker A, Leber A, Becker C et al. Predictive value of coronary calcifications for future cardiac events in asymptomatic individuals. Am Heart J 2008; 155: 154-160.
51. Lauer M. Screening asymptomatic subjects for subclinical atherosclerosis. JACC 2010; 56: 106-108.
52. Detrano R, Guerci AD, Carr JJ et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008; 358: 1336-1345.
53. Blaha MJ, Budoff MJ, DeFilippis AP et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet 2011; 378: 684-692.
54. Young LH, Wackers FJ, Chyun DA et al. DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009; 301: 1547-1555.
55. O'Malley PG. A double take on serial measurement of coronary artery calcification. Arch Intern Med 2009; 169: 2051-2052.